<?xml version="1.0" encoding="UTF-8"?>
<p id="Par35">
 <italic>UNITAID</italic> is a global health initiative, launched by the governments of five countries in 2006 as a non-profit organization partially financed by a small levy on airline tickets and part of one country’s tax on CO
 <sub>2</sub> emissions from air travel. Its main focus has been on HIV/AIDS, tuberculosis and malaria, but its strategic objectives for 2013–2016 include increasing access to treatment for co-infections with HBV and HCV. It disburses about US$ 200 million a year in grants. Through its mandate to work on co-infections, and focusing on the product rather than the disease, it does not pay for treatment cost but it is supporting WHO’s programme to prequalify medicines. In 2015, UNITAID’s Executive Board adopted a resolution [
 <xref ref-type="bibr" rid="CR24">24</xref>] supporting its need to focus strategically on the development of better tools to diagnose HCV infection, in particular in cases of HIV/HCV co-infection.
</p>
